Form 8K Pyxis Oncology Inc For: 13 August
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Pyxis Oncology Inc (PYXS)
Pyxis Oncology Inc stock price live, this page displays NASDAQ PYXS stock exchange data. View the PYXS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Pyxis Oncology Inc real time stock price chart below.
What Is the Pyxis Oncology Inc Stock Price Today?
The Pyxis Oncology Inc stock price today is 3.345.
What Is the Stock Symbol for Pyxis Oncology Inc?
The stock symbol for Pyxis Oncology Inc is "PYXS."
What Stock Exchange Does Pyxis Oncology Inc Trade On?
Pyxis Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Pyxis Oncology Inc a Good Stock to Buy?
Determining whether Pyxis Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PYXS quote. (ISIN: US7473241013)
What Is the Pyxis Oncology Inc Stock Price Today?
The Pyxis Oncology Inc stock price today is 3.345.
What Is the Stock Symbol for Pyxis Oncology Inc?
The stock symbol for Pyxis Oncology Inc is "PYXS."
What Stock Exchange Does Pyxis Oncology Inc Trade On?
Pyxis Oncology Inc is listed and trades on the NASDAQ stock exchange.
Is Pyxis Oncology Inc a Good Stock to Buy?
Determining whether Pyxis Oncology Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PYXS quote. (ISIN: US7473241013)
3.345
+0.355(+11.87%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.060
3.500
52 wk Range
1.030
5.550
PYXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.0603.500
52 wk Range
1.0305.550
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PYXS Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
7.222
Upside
+115.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings downwards for the upcoming period
Form 144 Pyxis Oncology For: 30 June- Investing.com
Pyxis Oncology receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Form 8K Pyxis Oncology Inc For: 13 August
- Investing.com
- Pyxis Oncology receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 7.222
(+115.91% Upside)
Pyxis Oncology Inc SWOT Analysis
ADC Innovation | Pyxis Oncology's novel antibody-drug conjugate technology shows promise in early trials, demonstrating efficacy across multiple tumor types |
Clinical Progress | Explore PYX-201's development, showcasing a favorable safety profile and potential advantages over existing ADCs in the competitive oncology landscape |
Market Potential | Analyst price targets range from $7 to $13, suggesting significant upside potential if upcoming data readouts prove successful |
Strategic Outlook | Delve into Pyxis's future prospects, balancing its innovative approach against financial constraints and intense market competition in cancer therapeutics |
Earnings
Latest Release
Aug 13, 2026
EPS / Forecast
-0.40 / -0.36
Revenue / Forecast
-- / 29.17K
Compare PYXS to Peers and Sector
Metrics to compare | PYXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPYXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.8x | −10.9x | −0.3x | |
PEG Ratio | −0.26 | −0.03 | 0.00 | |
Price/Book | 21.8x | 4.6x | 2.6x | |
Price / LTM Sales | 22.6x | 52.6x | 3.1x | |
Upside (Analyst Target) | 134.1% | 38.7% | 50.4% | |
Fair Value Upside | Unlock | −10.7% | 6.4% | Unlock |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Pyxis Oncology (PYXS) Stock Price Today?
The Pyxis Oncology stock price today is 3.345 USD.
What Stock Exchange Does Pyxis Oncology Trade On?
Pyxis Oncology is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Pyxis Oncology?
The stock symbol for Pyxis Oncology is "PYXS."
What Is the Pyxis Oncology Market Cap?
As of today, Pyxis Oncology market cap is 249.390M USD.
What Is Pyxis Oncology's Earnings Per Share (TTM)?
The Pyxis Oncology EPS (TTM) is -1.403.
When Is the Next Pyxis Oncology Earnings Date?
Pyxis Oncology will release its next earnings report on Nov 17, 2026.
From a Technical Analysis Perspective, Is PYXS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Pyxis Oncology Stock Split?
Pyxis Oncology has split 0 times.
How Many Employees Does Pyxis Oncology Have?
Pyxis Oncology has 56 employees.
What is the current trading status of Pyxis Oncology (PYXS)?
As of Aug 19, 2026, Pyxis Oncology (PYXS) is trading at a price of 3.345 USD, with a previous close of 2.990 USD. The stock has fluctuated within a day range of 3.060 USD to 3.500 USD, while its 52-week range spans from 1.030 USD to 5.550 USD.
What Is Pyxis Oncology (PYXS) Price Target According to Analysts?
The average 12-month price target for Pyxis Oncology is 7.222 USD, with a high estimate of 12 USD and a low estimate of 5 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +115.91% Upside potential.
What Is the PYXS Premarket Price?
PYXS's last pre-market stock price is 3.060 USD. The pre-market share volume is 2,790.000, and the stock has decreased by 0.070, or 2.340%.
What Is the PYXS After Hours Price?
PYXS's last after hours stock price is 3.040 USD, the stock has decreased by 0.050, or 1.670%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.